美国胃肠病学会临床诊疗路径在美国人群中用于非酒精性脂肪性肝病风险分层的表现
该研究利用2017-2018年美国国家健康与营养调查数据,评估美国胃肠病学会(AGA)非酒精性脂肪性肝病风险分层临床路径的表现。在2322名参与者中,FIB-4<1.3者LSM≥8 kPa的阴性预测值为90%,FIB-4 1.3-2.67者阳性预测值为13%。
要点
- AGA路径中FIB-4<1.3者LSM≥8 kPa的阴性预测值为90%,FIB-4 1.3-2.67者阳性预测值为13%。
- 作者提出替代策略:对FIB-4≥1.3且合并糖尿病者行VCTE,可减少VCTE数量并提高阳性预测值。
- 当前AGA临床路径会导致VCTE过度使用。
核心结论
- 实施当前AGA临床路径会导致VCTE过度使用,使用FIB-4≥1.3且糖尿病选择成人进行二线检测的替代策略可改善路径表现并减少不必要的VCTE。
主要发现
- 在FIB-4<1.3的参与者中,LSM≥8 kPa的阴性预测值为90%。
- 在FIB-4 1.3-2.67的参与者中,阳性预测值为13%。
关键数值与推荐
- AGA临床路径定义:FIB-4<1.3且LSM<8 kPa(通过振动控制瞬时弹性成像VCTE测量)与显著肝纤维化低风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The American Gastroenterological Association (AGA) recently launched the Clinical Care Pathway for the Risk Stratification and Management of Patients with NAFLD to identify adults with significant fibrosis. We aimed to examine this pathway's performance in the US population. APPROACH AND RESULTS: Using the 2017-2018 National Health and Nutrition Examination Survey data, we identified participants aged ≥18 with available Fibrosis-4 (FIB-4) score and liver stiffness measurement (LSM) in the absence of other liver diseases. Based on the AGA clinical pathway, FIB-4 < 1.3 and LSM < 8 kilopascals (kPa) by vibration-controlled transient elastography (VCTE) are associated with low risk of significant fibrosis. Using these cutoffs, we examined the pathway performance using negative predictive value (NPV) and positive predictive value (PPV) and explored alternative risk-stratification strategies. There were 2322 participants with available data (projected to 94.2 million US adults). The NPV of LSM ≥ 8 kPa among those with FIB-4 < 1.3 was 90%, whereas the PPV among those with FIB-4 1.3-2.67 was 13%. As diabetes was a strong predictor of fibrosis, we propose a simple, alternative strategy to eliminate the indeterminate FIB-4 range and perform VCTE in those with FIB-4 ≥ 1.3 and diabetes. This strategy would decrease the number of VCTEs from 14.5 to 4.9 million and increase PPV from 13% to 33% without compromising the NPV among those who did not undergo VCTE. CONCLUSION: The implementation of the current AGA clinical pathway would lead to overutilization of VCTE. An alternative strategy using FIB-4 ≥ 1.3 and diabetes to select adults undergoing second-line testing will improve this pathway's performance and minimize unnecessary VCTEs.
引用
- Udompap P, Therneau TM, Canning RE, et al. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology. 2023. PMID: 35989502. doi:10.1002/hep.32739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。